Columbia University Minority/Underserved Site NCI Community Oncology Research Program

项目摘要 赫伯特欧文综合癌症中心的少数民族/服务不足的国家社区肿瘤学 哥伦比亚大学欧文医学中心的研究项目（CIMCC/CUIMC/MU-NCORP）已经建立了 一个强大的基础设施，便于识别，激活和参与NCORP研究基地 临床试验CIMCC/CUIMC/MU-NCORP的总体目标是为癌症患者提供最好的癌症护理。 少数/不应得的人群包围我们的癌症中心。我们计划的具体目标是：1） 为我们的患者和医疗保健提供者社区提供并增强对NCI临床产品组合的访问 试验网络（NCTN/NCORP）试验，特别是在癌症控制，癌症预防的四个组成部分 和筛查，癌症护理提供（CCD）研究和癌症治疗（I，II，III期）以及组织 2）通过促进少数民族和服务不足的患者参与这些试验， 试验组合的可获得性和可用性，并确定和减少应计费用障碍，以满足需求 3）领导，参与和促进NCORP/NCTN在癌症领域的研究基础研究 护理连续体，特别关注减少医疗保健差异的研究，以及4）合作， 为NCI NCORP-wide活动做出贡献。在过去的四年里，这一强大的基础设施导致了许多 成就。我们的MU-NCORP产品组合包括150多项试验，我们已经招募了500多名患者 癌症控制和预防，癌症护理交付和治疗试验。我们一直超过 少数族裔和服务不足的患者群体的最低30%的应计目标。此外，我们还 在研究基地中发挥领导作用，并领导了许多试验。通过促进注册和参与， 少数和服务不足的癌症患者进入高影响力的临床试验，我们将实现我们的最终目标， 提高所有人的生存率和生活质量，无论年龄、种族、民族、性别、性取向如何 或社会经济地位。

PROJECT SUMMARY The Herbert Irving Comprehensive Cancer Center’s Minority/Underserved National Community Oncology Research Program at Columbia University Irving Medical Center (HICCC/CUIMC/MU-NCORP) has established a robust infrastructure that facilitates the identification, activation and participation in NCORP Research Base clinical trials. The overall goal of the HICCC/CUIMC/MU-NCORP is to provide the best in cancer care to the minority/undeserved population that surrounds our cancer center. The specific aims of our program are to 1) Provide and enhance access for our community of patients and healthcare providers to a portfolio of NCI Clinical Trials Network (NCTN/NCORP) trials, specifically in the four components of cancer control, cancer prevention and screening, cancer care delivery (CCD) research and cancer treatment (Phase I, II, III) as well as tissue acquisition; 2) Enhance the accrual of minority and underserved patients onto these trials by promoting the accessibility and availability of the trial portfolio and identifying and reducing accrual barriers to meet the needs of our community, 3) Lead, participate, and promote NCORP/NCTN research base studies across the cancer care continuum with a particular focus on studies that reduce healthcare disparities, and 4) Collaborate and contribute to the NCI NCORP-wide activities. Over the past four years, this strong infrastructure has led to many accomplishments. Our MU-NCORP portfolio consists of over 150 trials, and we have enrolled over 500 patients to Cancer Control and Prevention, Cancer Care Delivery and Therapeutic Trials. We have consistently exceeded the minimum 30% accrual target for minority and underserved patient populations. In addition, we have taken leadership roles within the research bases and lead many trials. By facilitating the enrollment and participation of minority and underserved cancer patients into high impactful clinical trials, we will achieve our ultimate goal of improving survival and quality of life of all individuals regardless of age, race, ethnicity, gender, sexual orientation or socioeconomic status.